Full Press Release Details
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034)
PRIMA BIOMED AWARDED JAPANESE PATENT FOR CVAC
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) is pleased to announce that it has been granted a patent from the Japanese
Patent Office that protects methods used in the manufacture of CVac. The method of use claims secured in patent number 5192020 entitled Use of mannose receptor-bearing antigen presenting cells for the manufacture of medicament for eliciting
cytotoxic T cell response to antigen provide for the treatment of patients with dendritic cells that have been pulsed with mannan fusion protein (M-FP) conjugated to an antigen, including but not limited to mucin 1.
Prima BioMed is a globally active biotechnology company. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging
its current technology and expertise to develop innovative treatment options for patients and to maximize value to shareholders. Prima s lead product is CVac , an autologous dendritic cell product currently in clinical trials for ovarian
cancer patients who are in remission.
For further information please contact:
Brown, Prima BioMed Ltd.
+1 (919) 710-9061; jessica.brown@primabiomed.com.au
Australia Investor/Media:
Mr. James Moses, Mandate Corporate
(0) 420 991 574; james@mandatecorporate.com.au
Europe Investor/Media:
Mr. Axel M hlhaus, edicto GmbH
(0) 69 905505-52; amuehlhaus@edicto.de
Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 9276 1284